Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex, Axel; Mulders, Peter; Jewett, Michael; Wagstaff, John; V van Thienen, Johannes; U Blank, Christian; van Velthoven, Roland; Del Pilar Laguna, Maria; Wood, Lori; H E van Melick, Harm; J Aarts, Maureen; B Lattouf, J; Powles, Thomas; Jan de Jong Md PhD, Igle; Rottey, Sylvie; Tombal, Bertrand; Marreaud, Sandrine; Collette, Sandra; Collette, Laurence; Haanen, John

doi:10.1001/jamaoncol.2018.5543

Public

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Published in JAMA oncology • Feb 1, 2019

NobleIDark:/48914/w1/20260526/51F7E874Record on NobleID

Authors:

Axel Bex

,

Peter Mulders

,

Michael Jewett

Abstract

Importance: In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective: To examine whether a period of sunitinib thera...

Discussions